TickerTalks
Browse all tickers →
TickerTalks›$NTRA
NTNTRA

Natera, Inc.

$NTRA·$33B·Medical - Diagnostics & Research·Healthcare
$231.41+2.2%YTD+1.1%1Y+34.7%
Mentions · last 7 days
2026-06-13: 2 posts2026-06-14: 1 posts2026-06-15: 4 posts2026-06-16: 3 posts2026-06-17: 8 posts2026-06-18: 14 posts2026-06-19: 3 posts35+9%
Price updated 12h ago·X counts updated 12h ago
NTNTRA
Natera, Inc.$NTRA
$231.41+2.19%35 posts+9%
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $NTRA.

Medical - Diagnostics & Research · Healthcare

Life science instrument demand is normalizing after the post-COVID destocking cycle — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials. AI-assisted drug discovery (SDGR, TWST) is creating incremental instrument and data demand on top of the recovery cycle.

Industry benchmark

10-name peer basket
+5.9%YTD
+24.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-144.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-11.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-13.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
13.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-15.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
65.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.56$-0.54-3.3%
Q4 2025Feb 26, 2026$0.35$-0.51+168.4%
Q3 2025Nov 6, 2025$-0.64$-0.39-65.9%
Q2 2025Aug 7, 2025$-0.74$-0.62-20.2%
Next earningsThu, Aug 6·consensus EPS $-0.49

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$696.6M+38.8%64.8%-13.4%$-0.60$18.0M
Q4 FY25$665.5M+39.8%67.1%-3.4%$0.35$37.8M
Q3 FY25$592.2M+34.7%64.9%-16.5%$-0.64$24.5M
Q2 FY25$546.6M+32.2%63.5%-20.2%$-0.74$11.7M

Forward consensus

5-year forecast · up to 15 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.8B$2.8B – $2.8B-$1.61-$1.80 – -$1.5114
FY27$3.3B$3.2B – $3.4B-$0.32-$1.61 – $0.9615
FY28$4.0B$4.0B – $4.0B$1.45-$1.17 – $4.4515
FY29$4.7B$4.6B – $4.8B$2.29$2.20 – $2.3611
FY30$5.5B$5.4B – $5.7B$4.89$4.70 – $5.057

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.80%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+12.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 136.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.545-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 16Rowan E ChapmanDirector3.0K sh$643KSellJun 15Jonathan SheenaCO-FOUNDER3.1K sh$665KSellJun 15Matthew RabinowitzChair50.0K sh$10.7MSellJun 12Matthew RabinowitzChair50.0K sh$10.7MSellJun 5Marcus Gail BoxerDirector11.0K sh$2.4MSellJun 4Chapman Steven LeonardCEO41.1K sh$9.1MSellJun 1Solomon MoshkevichPresident2.4K sh$529K
+ 1 other (1 exempt) in window

See when $NTRA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-K/AOfficer or director change (amended)Jun 168-K/A — Item 5.02: Officer or director change
AI summary

Natera, Inc. filed an 8-K/A amending its original June 5, 2026 filing to report that the Board increased from 11 to 12 members and appointed Thomas Lynch as a Class I director effective June 2, 2026, with a term expiring at the 2028 annual meeting. Lynch's appointment follows no arrangement or understanding with any third party. This amendment corrects or supplements the original disclosure (Job 29); the substantive event is unchanged. Routine board addition of an independent director to Natera's growing genomics company board.

8-KOfficer or director changeJun 168-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Natera, Inc. held its 2026 Annual Meeting on June 11, 2026, at which stockholders approved an amendment to the Amended and Restated 2015 Equity Incentive Plan increasing the reserved share pool by 3.2 million shares. The Annual Meeting also included director elections and other routine proposals (results not fully detailed in the excerpt). The filing also covers the Thomas Lynch board appointment described in a companion 8-K (Job 29). The 3.2M share increase is mildly dilutive, providing runway for employee equity grants as Natera scales its genomics testing business.

3New insider — initial holdingsJun 93
AI summary

Thomas J. Lynch, Jr. filed a Form 3 (initial statement of beneficial ownership) for Natera, Inc. following his appointment as a new Class I board member effective June 2, 2026. The filing is addressed c/o Natera's Austin, Texas headquarters. Initial share ownership figures are not visible in the available excerpt. Routine administrative SEC filing accompanying the new board appointment.

8-KOfficer or director changeJun 58-K — Item 5.02: Officer or director change
AI summary

Natera's Board of Directors voted to increase its size from 11 to 12 members and appointed Thomas Lynch as a Class I director, effective June 2, 2026, with a term expiring at the 2028 annual meeting of stockholders. There is no arrangement or understanding between Lynch and any third party concerning his appointment. An 8-K/A (Job 22) was subsequently filed to amend or supplement this disclosure. Routine board expansion adding one independent director.

3New insider — initial holdingsApr 93
8-KOfficer or director changeApr 18-K — Item 5.02: Officer or director change
+ 13 other (4 13Gs · 3 earnings 8-Ks · 2 proxys · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congressbusinesswire.com·2d agoNatera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·8d agoNTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRCzacks.com·12d agoNatera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancerbusinesswire.com·16d agoHere's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)fool.com·17d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$A$DHR$GH$TWST$IQV$ICLR$TMO$STIM
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport